Immunohistochemistry and personalised medicine in lung oncology: Advantages and limitations;Immunohistochimie et médecine personnalisée en oncologie pulmonaire: Potentialités et limites

Bulletin du Cancer

Volumn 101, Issue 10, 2014, Pages 958-965

  Hofman, Véronique ^a   Ilie, Marius ^a   Long, Elodie ^a   Lassalle, Sandra ^a   Butori, Catherine ^a   Bence, Coraline ^a   Washetine, Kevin ^a   Lalvee, Salomé ^a   Hofman, Paul ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Accreditation; Immunohistochemistry; Lung cancer; Molecular biology; Personalized medicine; Targeted therapy

Indexed keywords

ANTIBODY; FORMALDEHYDE; PARAFFIN;

CANCER PATIENT; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; LUNG CANCER; MOLECULAR BIOLOGY; ONCOLOGY; PERSONALIZED MEDICINE; QUALITY CONTROL; REVIEW; DIAGNOSTIC USE; GENETICS; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; MUTATION; PROCEDURES;

ANTIBODIES; HUMANS; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION;

EID: 84908701303     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2014.2041     Document Type: Article

References (43)

1. Liu Q, Zhou Q. The challenge of lung cancer in China. J Cancer Res Ther 2013 ; S2 : 65-6.
2. Raaschou-Nielsen O, Andersen ZJ, Beelen R, et al. Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol 2013 ; 14 : 813-22.
3. Crinò L, Weder W, van Meerbeeck J, Felip E, ESMO Guidelines Working Group E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 ; 21 (Suppl 5) : v103-15.
4. Ilie M, Hofman P. Pitfalls in lung cancer molecular pathology: how to limit them in routine practice? Curr Med Chem 2012 ; 19 : 2638-51.
5. Long E, Hofman V, Ilie M, et al. Mise en place d'un secteur de pathologie moléculaire en oncologie au sein d'un laboratoire d'anatomie pathologique (LPCE, CHU de Nice). Ann Pathol 2013 ; 33 : 24-37.
6. Han XH, Zhang NN, Ma L, et al. Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer. Virchows Arch 2013 ; 463 : 583-91.
7. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010 ; 16 : 1561-71.
8. Sholl LM, Weremowicz S, Gray SW, et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 2013 ; 8 : 322-8.
9. Ying J, Guo L, Qiu T, et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol 2013 ; 24 : 2589-93.
10. Dziadziuszko R, Wynes MW, Singh S, et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 2012 ; 7 : 340-7.
11. Tsuta K, Kozu Y, Mimae T, et al. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol 2012 ; 7 : 331-9.
12. Ilie M, Long E, Hofman V, et al. Diagnostic value of immunohistochemistry for the detection of the BRAF V600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 2013 ; 24 : 742-8.
13. Sholl LM, Sun H, Butaney M, Zhang C, Lee C, Jänne PA. ROS1 Immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol 2013 ; 37 : 1441-9.
14. Yoshida A, Tsuta K, Wakai S, et al. Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod Pathol 2014 ; 4 : 711-20.
15. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010 ; 12 : 169-76.
16. Fan X, Liu B, Xu H, et al. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples. Hum Pathol 2013 ; 44 : 1499-507.
17. Hofman P, Ilie M, Hofman V, et al. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol 2012 ; 23 : 1738-43.
18. Ilie MI, Hofman V, Bonnetaud C, et al. Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Arch 2010 ; 457 : 483-95.
19. Isaksson S, Bendahl PO, Salomonsson A, et al. Detecting EGFR alterations in clinical specimens-pitfalls and necessities. Virchows Arch 2013 ; 463 : 755-64.
20. Kitamura A, Hosoda W, Sasaki E, Mitsudomi T, Yatabe Y. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 2010 ; 16 : 3349-55.
21. Hewitt SM, Lewis FA, Cao Y, et al. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 2008 ; 132 : 1929-35.
22. Hofman V, Ilie M, Gavric-Tanga V, et al. Role du laboratoire d'anatomie-pathologique dans l'approche pré-analytique des examens de biologie moléculaire realisés en pathologie tumorale. Ann Pathol 2010 ; 30 : 85-93.
23. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 2008 ; 99 : 929-35.
24. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011 ; 29 : 2972-7.
25. Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res 2013 ; 73 : 2381-8.
26. Reck M. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Ann Oncol 2012 ; 23 (Suppl 8) : viii28-34.
27. Long E, Hofman V, Ilie M, et al. Accréditation de l'activité de pathologie moléculaire selon la norme ISO 15189. Principales étapes à respecter et principaux écueils possibles. Ann Pathol 2013 ; 33 : 12-23.
28. Hofman P. Quel matériel biologique et comment ? Rev Fr Mal Respir 2011 ; 3 : 157-60.
29. Long E, Ilie M, Hofman V, et al. Rôle du pathologiste dans la prise en charge des tissus en oncologie. Bull Cancer 2013 ; 100 : 837-45.
30. Bussolati G, Chiusa L, Cimino A, D'Armento G. Tissue transfer to pathology labs: under vacuum is the safe alternative to formalin. Virchows Arch 2008 ; 452 : 229-31.
31. Hofman P. Quels fixateurs ? Pour quelles indications ? Principaux critères d'évaluation des méthodes alternatives à la fixation du formol. Rev Fr Lab 2009 ; 408 : 1-4.
32. Stanta G, Mucelli SP, Petrera F, Bonin S, Bussolati G. A novel fixative improves opportunities of nucleic acids and proteomic analysis in human archive's tissues. Diagn Mol Pathol 2006 ; 15 : 115-23.
33. Werner M, Chott A, Fabiano A, Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 2000 ; 24 : 1016-9.
34. Washetine K, Long E, Hofman V, et al. L'accréditation selon la norme ISO 15189 d'un laboratoire de pathologie et de génétique somatique (LPCE, CHU de Nice) : retour d'expérience. Ann Pathol 2013 ; 33 : 386-97.
35. Ilie M, Hofman P. The potential value of immunohistochemistry as a screening tool for oncogenic targets of personalized lung cancer therapy. J Oncopathol 2013 ; 1 : 82-92.
36. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995 ; 48 : 876-8.
37. Marin C, Beauchet A, Capper D, et al. Detection of BRAF p.V600E mutations in melanoma by immunohistochemistry has a good interobserver reproducibility. Arch Pathol Lab Med 2013.
38. Ilie M, Long E, Hofman V, et al. Les méthodes de séquenc¸age de «nouvelle génération» (NGS) et le cancer broncho-pulmonaire : intérêt, principales technologies, applications et limites actuelles. Rev Fr Lab 2014 ; 458 : 51-8.
39. Loi no 2013-442 du 30 mai 2013 portant réforme de la biologie médicale. Journal Officiel de la République Franc¸aise 2013 ; 1-140.
40. Hofman V, Ilie M, Long-Mira E, et al. Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients. J Invest Dermatol 2013 ; 133 : 1378-81.
41. Ilie M, Long E, Butori C, et al. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Ann Oncol 2012 ; 23 : 2907-13.
42. Scarpa A, Sikora K, Fassan M, et al. Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS One 2013 ; 13 : 8.
43. Scott MG, Smith BR, Wu AH, Young IS, Plebani M, Chiu RW. How well are we training the next generation of clinical pathologists and clinical laboratory directors? A global perspective. Clin Chem 2012 ; 58 : 491-5.